Zoster vaccine is not routinely recommended for adults aged 50–59 years.

The incidence of herpes zoster in people aged 50–59 years is higher than people aged <50 years,4,7 and zoster vaccine is efficacious in this age group.8 However, the likelihood of developing herpes zoster, post-herpetic neuralgia and other complications of herpes zoster is lower in this age group than in people ≥60 years of age.9,10

People aged 50–59 years who want to reduce their risk of herpes zoster can receive zoster vaccine. However, the exact duration of vaccine efficacy is not known. Protection after a single vaccine dose wanes over time.2,3 The need for revaccination is not yet determined.

See Vaccine information and Epidemiology.

Page history

Last updated: 
13 January 2021
Last reviewed: 
13 January 2021